The phase 3 KEYNOTE-B21 study missed its primary end point, as pembrolizumab plus chemotherapy did not improve disease-free survival in newly diagnosed, high-risk endometrial cancer.
Pembrolizumab (Keytruda) plus adjuvant chemotherapy with or without radiotherapy did not improve disease-free survival (DFS) in patients with newly diagnosed, high-risk endometrial cancer, missing the primary end point of the phase 3 KEYNOTE-B21 study (NCT04634877).1
“While these results were not what we had hoped, we are focused on continuing to build on the established role of [pembrolizumab] in advanced endometrial carcinoma through our approved indications, while rapidly progressing clinical research evaluating [pembrolizumab]-based combinations and other investigational candidates, including antibody-drug conjugates, in endometrial and other types of gynecologic malignancies,” said Gursel Aktan, MD, PhD, vice president, global clinical development, Merck Research Laboratories, in a press release.
A prespecified interim analysis for KEYNOTE-B21 was planned. Here, it was observed that the data for pembrolizumab plus chemotherapy with or without radiotherapy did not meet the statistical criteria for DFS compared with placebo plus chemotherapy with or without radiotherapy. The dual primary end point of overall survival (OS) was not analyzed as DFS was not reached.
The safety profile of pembrolizumab was consistent with previous reports, and no new safety signals were identified.
Pembrolizumab is currently FDA-approved in 2 endometrial cancer indications: in combination with lenvatinib (Lenvima) in mismatch repair-proficient (pMMR) or not microsatellite instability-high (MSI-H) advanced endometrial cancer that has progressed following prior therapy or as a single agent in MSI-H or MMR deficient endometrial cancer that has progressed following prior therapy and is not suitable for surgery or radiation.
In February 2023, Merck announced findings from the KEYNOTE-868/NRG-GY018 study (NCT03914612) that pembrolizumab plus carboplatin and paclitaxel improved progression-free survival in patients with stage III to IV or recurrent endometrial cancer, regardless of MMR status.2 Additionally, data presented at the 2024 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer in March showed that this combination improved OS in the intent-to-treat population.3
The FDA granted priority review for the supplemental biologic license supported by KEYNOTE-868, and the Prescription Drug User Fee Act target action date of June 21, 2024.1
FDA Accepts sBLA of Dostarlimab/Chemo to Include All Advanced Endometrial Cancer
April 24th 2024The FDA accepted the supplemental biologics license for dostarlimab plus standard-of-care chemotherapy for all patients with primary advanced or recurrent endometrial cancer and set a Prescription Drug User Fee Act action date of August 23, 2024.
Read More
Roundtable Roundup: Surveying Oncologists on Endometrial Cancer Treatment
March 27th 2024Bhavana Pothuri, MD, and Krishnansu S. Tewari, MD, discussed the treatment options of a patient with advanced endometrial cancer and participants chose an immune checkpoint inhibitor to use for therapy.
Read More